Expertise in
13
conditions

Thomas R. Pieber

Graz, AT 
Expertise in
13
conditions
Graz, AT 

Overview

Thomas Pieber practices practicing medicine in Graz, Austria.

Mr. Pieber is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Low Blood Sugar, Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), Gastric Bypass, and Bone Graft.

He is actively involved in clinical research, co-authoring 333 peer reviewed articles and participating in 11 clinical trials.

Gender

Male

Locations

Graz, Austria
Other Locations
Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)
Enrollment Status: Completed
Publish Date: May 20, 2026
Intervention Type: Drug
Study Drug: Verapamil SR
Study Phase: Phase 2
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
Enrollment Status: Completed
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drug: Anti-Human Thymocyte Immunoglobulin, Rabbit
Study Phase: Phase 2
A Randomized, Placebo-Controlled, Crossover Study to Investigate the Effect of Once-Weekly Tirzepatide on the Counter-Regulatory Response to Hypoglycemia in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled, Crossover Study to Investigate the Effect of Once-Weekly Tirzepatide on the Counter-Regulatory Response to Hypoglycemia in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: May 20, 2024
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 1
An Exploratory Study in Healthy Volunteers to Investigate the Cross-talk Between Local Drug Concentrations in the Skin and Systemic Concentrations During Topical Bioequivalence Studies Using Dermal Sampling Techniques
An Exploratory Study in Healthy Volunteers to Investigate the Cross-talk Between Local Drug Concentrations in the Skin and Systemic Concentrations During Topical Bioequivalence Studies Using Dermal Sampling Techniques
Enrollment Status: Completed
Publish Date: February 10, 2023
Intervention Type: Procedure, Drug, Device
Study Phase: Not Applicable
A Single Center, Open-label, Clinical Study to Evaluate the Ability of Dermal Open Flow Microperfusion (dOFM) for Bioequivalence Testing of Topically Applied Diclofenac Sodium Products in Healthy Subjects
A Single Center, Open-label, Clinical Study to Evaluate the Ability of Dermal Open Flow Microperfusion (dOFM) for Bioequivalence Testing of Topically Applied Diclofenac Sodium Products in Healthy Subjects
Enrollment Status: Completed
Publish Date: August 26, 2022
Intervention Type: Device, Drug, Procedure
Study Phase: Not Applicable
Comparison of the Impact of Biphasic Insulin Aspart 30 (BiAsp 30), Biphasic Insulin Aspart 70 (BiAsp 70) and Insulin Aspart on Postprandial Glucose and Lipid Metabolism During Two Consecutive Meals in Type 2 Diabetics.
Comparison of the Impact of Biphasic Insulin Aspart 30 (BiAsp 30), Biphasic Insulin Aspart 70 (BiAsp 70) and Insulin Aspart on Postprandial Glucose and Lipid Metabolism During Two Consecutive Meals in Type 2 Diabetics.
Enrollment Status: Completed
Publish Date: June 30, 2021
Intervention Type: Drug
Study Phase: Phase 4
An Exploratory Study in Healthy Volunteers to Identify Factors Influencing Bioequivalence Studies on Moderately Lipophilic Drugs Using Dermal Open Flow Microperfusion (dOFM)
An Exploratory Study in Healthy Volunteers to Identify Factors Influencing Bioequivalence Studies on Moderately Lipophilic Drugs Using Dermal Open Flow Microperfusion (dOFM)
Enrollment Status: Completed
Publish Date: October 12, 2020
Intervention Type: Procedure, Drug, Device
Study Phase: Not Applicable
G-Pen (Glucagon Injection) Compared to GlucaGen® Hypokit® (Glucagon) for Induced Hypoglycemia Rescue in Adults With T1D: A Phase 3 Multi-center, Randomized, Controlled, Single Blind, 2-way Crossover Study to Evaluate Efficacy and Safety
G-Pen (Glucagon Injection) Compared to GlucaGen® Hypokit® (Glucagon) for Induced Hypoglycemia Rescue in Adults With T1D: A Phase 3 Multi-center, Randomized, Controlled, Single Blind, 2-way Crossover Study to Evaluate Efficacy and Safety
Enrollment Status: Completed
Publish Date: May 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
Blood Glucose Response After Oral Intake of Lactulose (Laevolac®) in Mildly Constipated Patients With Diabetes Mellitus Type 2
Blood Glucose Response After Oral Intake of Lactulose (Laevolac®) in Mildly Constipated Patients With Diabetes Mellitus Type 2
Enrollment Status: Completed
Publish Date: April 12, 2019
Intervention Type: Drug
Study Phase: Phase 4
An Open-label, Multi-centre, Randomised, 2-period Cross-over Study to Assess the Efficacy and Safety of Closed Loop Insulin Delivery Using Diluted Insulin in Comparison With Closed Loop With Non-diluted Insulin Over 21 Days in Children With Type 1 Diabetes Aged 1 to 7 Years in the Home Setting
An Open-label, Multi-centre, Randomised, 2-period Cross-over Study to Assess the Efficacy and Safety of Closed Loop Insulin Delivery Using Diluted Insulin in Comparison With Closed Loop With Non-diluted Insulin Over 21 Days in Children With Type 1 Diabetes Aged 1 to 7 Years in the Home Setting
Enrollment Status: Completed
Publish Date: June 06, 2018
Intervention Type: Device
Study Phase: Not Applicable
View 9 Less Clinical Trials

333 Total Publications

Mid-infrared wearable biosensing for metabolic syndrome: Opportunities and translational challenges.
Mid-infrared wearable biosensing for metabolic syndrome: Opportunities and translational challenges.
Journal: iScience
Published: July 23, 2026

Frequently Asked Questions about Thomas R. Pieber

Is Thomas R. Pieber a top-rated expert for Low Blood Sugar?

MediFind is an objective health platform that identifies experts based on real-world data. Thomas R. Pieber is classified as an Elite expert for Low Blood Sugar, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Thomas R. Pieber participate in research or clinical trials?

Yes. Thomas R. Pieber has published 333 articles and abstracts on conditions like Low Blood Sugar. You can view a list of Thomas R. Pieber's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Pieber's expertise for a condition
ConditionClose
View All 33 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile